Braveheart Bio (BRVE) looks undervalued in late-stage HCM with funded Phase 3 trials, strong cash runway and nHCM upside.

Vijay Deverakonda shared insights on his film 'Ranabaali' at a promotional event in Vijayawada. The film aims to convey a ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Braveheart Bio shares rose 5.5% after the company began its pivotal Phase 3 trial of BHB-1893 and reported financial results supporting development of two late-stage programmes.

Braveheart Bio, a biotechnology company focused on developing therapies for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, has launched with $185 million in Series A ...

SHANGHAI and SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- Hengrui Pharma (Hengrui), and Braveheart Bio today announced results from a multi-center, randomized, open-label Phase 2 dose-ranging study ...

Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated All share and per share amounts for all periods presented have been retroactively adjusted to give ...